Sm08502-onc-01
http://www.usalifesciences.com/us/portal/news_details.php?news_id=28606851k$SnKVXke2weSNs Webb1 aug. 2024 · HEC265, SNGM, and Ishikawa-S33Y tumors all had significantly lower tumor volumes with combination of SM08502 and paclitaxel compared to single-agent …
Sm08502-onc-01
Did you know?
Webb29 sep. 2024 · add_box. SAN DIEGO, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering … Webb17 nov. 2024 · Drug: SM08502 Study Type Interventional Enrollment (Actual) 82 Phase Phase 1 Contacts and Locations This section provides the contact details for those …
Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC … Webb6 apr. 2024 · SM08502 (cirtuvivint) is a novel pan CDC-like kinase (CLK) and Dual specificity tyrosine kinase (DYRK) inhibitor that targets mRNA splicing and is optimized …
Webb13 dec. 2024 · SM08502 inhibited cell viability in all 14 cell lines (regardless of KRAS status) (EC 50 =0.072-0.526 μM). In Capan-1, HPAFII, and Panc1 cells, 1 μM SM08502 … Webb15 aug. 2024 · Abstract. Dysregulation of the cyclin D-CDK4/6-RB signaling axis is implicated in HR+ breast cancer (BC). While CDK4/6 inhibitors such as palbociclib …
Webb2 okt. 2024 · SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of data demonstrating a novel mechanism of action for SM08502 …
Webb28 nov. 2024 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors The safety and scientific validity of … fly kathmandu to pokharaWebb1 sep. 2024 · Characterization of SM08502, a small-molecule CLK inhibitor of Wnt activity. (A) SM08502 inhibited the activity of CLK kinases. CLK2, CLK3, and CDK1 kinase IC 50 s … fly kbh parisWebbSM08502-ONC-01: A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with … fly kbh hamburgWebbCancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically … greenmount village community walking groupWebbThe Botanical Supplements Market is Estimated to Reach a Market Size Worth us$39.767 Billion by 2027 United States Liquid Biopsy Market Expected to Grow at Double-Digit … greenmount veterinary nursingfly kathmandu to lhasaWebb31 mars 2024 · In an iterative screening campaign of >1500 compounds, SM08502 was developed as a small-molecule CLK inhibitor with IC 50 values of 0.002 μM for CLK2 and … fly kc